Patients must have had =<  prior cytotoxic regimen for metastatic disease (unless enrolling in the Progressive Brain Metastases Cohort); note that endocrine and immunotherapies do not count as cytotoxic regimens
With the exception of steroid pretreatment or the administration of intrathecal cytarabine, patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of B-ALL or any cancer diagnosed prior to the initiation of protocol therapy on AALL; patients cannot have secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy; patients receiving prior steroid therapy may be eligible for AALL
Cytotoxic therapy: at least  days since the completion of cytotoxic therapy with the exception of hydroxyurea, which is permitted up to  hours prior to the start of protocol therapy, or maintenance chemotherapy, or intrathecal chemotherapy (methotrexate strongly preferred) administered at the time of the required diagnostic lumbar puncture to establish baseline CNS status
Patients who have received treatment with any other cytotoxic chemotherapy prior to beginning protocol therapy (other than allowed in above criteria) are excluded
Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of ALCL or any cancer diagnosed previously are not eligible
ALL developing after a previous cancer treated with cytotoxic chemotherapy
Patients who have received any prior cytotoxic chemotherapy or biologics for sex cord-stromal tumors (SCSTs)
Subjects who have received any cytotoxic chemotherapy within the last  days prior to biopsy
Patients with AML must be unlikely to benefit from cytotoxic chemotherapy defined by any one of the following criteria:
Must not have received cytotoxic chemotherapy within  days of entry on to this study
Cytotoxic chemotherapy - weeks
Patients must be willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocol
Patients who have received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor are excluded
Cytotoxic chemotherapy or immunotherapy within  weeks of study entry
Prior cytotoxic chemotherapy is allowed.
Any cytotoxic chemotherapy within  days prior to initiation of study drug.
Prior cytotoxic chemotherapy and/or radiation therapy within  weeks of treatment
Patients must not have received more than  prior lines of cytotoxic chemotherapy for advanced disease; treatment with targeted agents or biologic agents such as antibodies as single agents will not count as a line of cytotoxic chemotherapy
received cytotoxic chemotherapy for either metastatic HSPC or CRPC within the last  weeks or other investigational agents within  weeks
>=  weeks off cytotoxic chemotherapy
Received any other investigational agent or systemic cytotoxic chemotherapy within the preceding  weeks
Chemotherapy: at least  weeks since prior cytotoxic chemotherapy
Conventional cytotoxic chemotherapy: ? weeks
Patients must be willing to forego other cytotoxic and non-cytotoxic therapies against the tumor while being treated on this protocol
Patients who have received prior cytotoxic, non-cytotoxic or experimental drug therapies for brain tumor are excluded
In the absence of rapidly proliferative disease, the interval from prior treatment to time of initiation will be at least  days for cytotoxic or non-cytotoxic (immunotherapy) agents.
Patients cannot be on a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide); they cant be on telotristat ethyl; previous use is acceptable if the patient has been off for over one month
Treatment with cytotoxic chemotherapy within  months prior to enrollment
Patients currently on cytotoxic chemotherapy or immunotherapy are eligible, not including anti-VEGF therapy
Has received cytotoxic chemotherapy for post-transplant relapse prior to study entry
Any prior myeloma-directed therapy including cytotoxic chemotherapy, biologic therapy, or radiotherapy within  weeks of enrollment
The subject has received cytotoxic chemotherapy, molecular targeted therapy, or immunotherapy within  days before the first dose of study drug (trametinib)
A  weeks interval from any investigational agents or cytotoxic chemotherapy to start of study is required
Prior therapy requirements:\r\n* Wt-GIST: previously untreated participants are eligible\r\n* PHEO/PGL with germline SDH subunit mutation: I-methyl-iodobenzylguanine (MIBG) in patients with MIBG avid tumors or cytotoxic chemotherapy (cyclophosphamide, vincristine, and dacarbazine [CVD] or temozolomide) is required prior to enrollment on this trial; however, patients who have refused cytotoxic chemotherapy or for whom treatment on this protocol prior to receiving cytotoxic chemotherapy is felt to be in the best interest for the patient by the local investigator will also be eligible\r\n* HLRCC-associated renal cell cancer: previously untreated participants are eligible
Last dose of any systemic non-taxane cytotoxic chemotherapy completed at least one day prior to Day . Last dose of any systemic taxane cytotoxic chemotherapy completed at least  weeks prior to Day 
Subjects receiving cytotoxic chemotherapy
Be at least  days from last administration of cytotoxic chemotherapy or other investigational agent
Prior cytotoxic chemotherapy or radiotherapy for this lymphoma
PHASE  ONLY: Patient participants previously untreated for AML who are considered unfit for cytotoxic chemotherapy by virtue of performance status, comorbidities, advanced age and/or low likelihood of response based on disease characteristics, or who decline cytotoxic induction chemotherapy
Patients must have been previously treated, as defined by treatment with at least one prior cytotoxic chemotherapy regimen or agent; patients may have received any number of prior cytotoxic agents
Prior systemic chemotherapy or radiation therapy for urothelial carcinoma or cytotoxic chemotherapy for another malignancy within  year of study entry are ineligible
Patients must be >=  days from previous cytotoxic treatment
Cytotoxic chemotherapy within  days prior to enrollment
Chemotherapy: cytotoxic (At least  days since last dose of chemotherapy prior to first dose of tazemetostat)
Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) (At least  days since last dose of non-cytotoxic chemotherapy prior to first dose of tazemetostat)
At the time of registration, patient must be at least  weeks from other prior cytotoxic chemotherapy
No intention to use cytotoxic chemotherapy within the next  months
Treatment with cytotoxic chemotherapy within previous  days, or failure to recover from adverse events (AEs) due to cytotoxic chemotherapy administered more than  days previous (however, ongoing neuropathy is permitted)
Prior cytotoxic chemotherapy or molecularly-targeted agents (e.g. erlotinib, crizotinib), unless >  years prior
Ongoing treatment with cytotoxic therapy
Patients with active cytotoxic chemotherapy or radiation therapy are excluded
Cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within  weeks before the first dose of study treatment
Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC; Note: sipulecel-T is permitted with a -week washout
Subjects who have any previous treatment with DNA-damaging cytotoxic chemotherapy (prior taxane chemotherapy allowed).
Has been treated with more than two lines of cytotoxic chemotherapy or molecular targeted therapy or interferon for Lung NET
Must not have received cytotoxic chemotherapy within  days of entry on to this study
Has had prior systemic cancer cytotoxic chemotherapy within the past four weeks at the time of the start of the lymphodepletion regimen
Prior treatment with cytotoxic chemotherapy for advanced NSCLC
 weeks from cytotoxic agents
 week from non-cytotoxic agents
Patients must be willing to forego other cytotoxic and non-cytotoxic drug or radiation therapy against the tumor while enrolled in the study.
Last cytotoxic chemotherapy  or more days or biologic therapy treatment  or more days before study start (greater than or equal to  days if nitrosourea was administered)
Eligible subjects must have completed appropriate treatment for their primary disease and be off cytotoxic chemotherapy and any immunosuppressive agents such as systemic steroids for at least  days prior to enrollment; patients should continue trastuzumab monotherapy throughout the course of this protocol; concurrent hormonal and biphosphonate therapies are allowed
No prior cytotoxic chemotherapy for metastatic disease; prior immunotherapy is permitted
Patients treated with prior chemotherapy, cytotoxic chemotherapy, radiation, biotherapy, or any investigational agent >  days prior to lymph node removal are eligible
 weeks from prior cytotoxic therapy
Prior treatment with any cytotoxic chemotherapy in metastatic setting; prior treatment with cytotoxic chemotherapy is allowed only if used in neoadjuvant, adjuvant or for bladder preserving protocols, as long as was administered >  months prior to starting study
Patients may not be on any cytotoxic chemotherapy or hormonal treatment for breast cancer during protocol treatment; (trastuzumab is allowed in HER positive patients)
Cytotoxic therapy: at least  days since the completion of cytotoxic therapy with the exception of hydroxyurea, low dose cytarabine, and intrathecal chemotherapy which is permitted up to  hours prior to the start of protocol therapy; for patients with aggressive disease that is in the peripheral blood and rising, this  day washout period may be omitted
Prior cytotoxic chemotherapy or radiotherapy for this lymphoma
Cytotoxic chemotherapy, steroids or monoclonal antibody (Mab) within  weeks of enrollment, except anti-Tac Mab (i.e. daclizumab) which cannot be used within  weeks of enrollment; hydroxyurea is considered different from cytotoxic chemotherapy and may be used up to the day before enrollment providing it is not increased during the week prior to enrollment and that the patients disease burden is not decreasing during that time
Concurrent treatment with any cytotoxic therapy
Chemotherapy: cytotoxic (At least  days since last dose of chemotherapy prior to first dose of tazemetostat)
Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) (At least  days since last dose of non-cytotoxic chemotherapy prior to first dose of tazemetostat)
No more than  total previous regimens of systemic therapy, including cytokines and cytotoxic chemotherapy.
Cytotoxic chemotherapy within  days before randomization
Cancer for which intraperitoneal cytotoxic chemotherapy is planned
Eligible for cytotoxic chemotherapy
Chemotherapy: cytotoxic At least  days
Prior cytotoxic chemotherapy;
No prior cytotoxic chemotherapy to treat their metastatic disease
Cytotoxic chemotherapy within  weeks of first trilaciclib (GT) dose
Cytotoxic chemotherapy; at least  days since last dose
Any prior cytotoxic chemotherapy regimen, including antibody drug conjugates for RCC or cytotoxic chemotherapy within  weeks of study treatment for OCCC
Prior treatment with greater than (>)  cytotoxic chemotherapy regimen for metastatic breast cancer
Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within  weeks of the first dose of study medication
Prior cytotoxic chemotherapy for metastatic prostate cancer. Prior cytotoxic chemotherapy with curative intent in the neoadjuvant or adjuvant setting is allowed but must have been completed at least  months prior to registration. No cytotoxic chemotherapy is allowed during protocol specified therapy.
Age > or equal to  years; patients younger than  who are unsuitable for or unwilling to receive standard cytotoxic chemotherapy are also eligible to be enrolled
Investigation or cytotoxic therapy within  days or nitrosoureas within  days of the first treatment with G-
Up to  prior cytotoxic regimens for advanced or metastatic breast cancer patients with no prior cytotoxic regimens for advanced or metastatic disease will only be allowed if they relapsed during or within  months of (neo-) adjuvant cytotoxic therapy that included a taxane and/or anthracycline, if not contraindicated.
Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within  days of the first dose of trial medication
Less than  days from the completion of any previous cytotoxic chemotherapy (with the exception of hydroxyurea)
Cytotoxic chemotherapy within the  days prior to randomization
Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC.
Patients who have received no more than  prior cytotoxic treatment regimen.
No cytotoxic chemotherapy within  weeks of starting study treatment
Prior cytotoxic chemotherapy for the treatment of CRPC, including taxanes, mitoxantrone and estramustine
Subject with rapidly progressing visceral disease who has not received and is thought to be able to tolerate cytotoxic chemotherapy. (However, subject who has previously received cytotoxic chemotherapy is permitted).
Patients must be at least  days post cytotoxic chemotherapy prior to enrollment
At least  days from the completion of any previous cytotoxic chemotherapy or biological therapy at time of initiation of POL.
Having recovered from prior surgery, radiation, chemotherapy (cytotoxic and noncytotoxic) to toxicity grade =<  or returned to baseline; previous treatment with immunotherapies, cytotoxic drugs, or other targeted agents is permitted; if cytotoxic chemotherapy was previously received, the last dose must be >=  month before leukapheresis; for other agents, the last dose must be >=  days before leukapheresis
Prior use of cetuximab or another epidermal growth factor receptor (EGFR) inhibitor is allowable and if used as a single agent should not be considered as a cytotoxic chemotherapy (nor should other targeted therapies be considered as a prior line of cytotoxic chemotherapy)
Previous cytotoxic chemotherapy for advanced (metastatic) disease
Patient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within  weeks of study
Subjects should have received no anti-leukemic therapy (except hydroxyurea) prior to the first dose of crenolanib as follows: for  days for classical cytotoxic agents and for five times the t/ (half-life) for FLT inhibitors and antineoplastic agents that are neither cytotoxic nor FLT inhibitors (e.g. hypomethylating agent or MEK inhibitor)
All previous cytotoxic chemotherapy, monoclonal antibody therapy, immune therapy should be washed out  weeks before apheresis and must be completed at least  weeks prior to pre-infusion lymphodepletive chemotherapy.
Prior bevacizumab and any cytotoxic chemotherapy
More than  prior lines of cytotoxic chemotherapy
Cytotoxic chemotherapy: ? duration of the most recent cycle of the previous regimen (a minimum of  weeks for all)
Planned cytotoxic chemotherapy during the SRS or WBRT
No prior treatment with cytotoxic chemotherapy
No cytotoxic chemotherapy within  days prior to registration for protocol therapy.
Most recent cytotoxic chemotherapy, immunotherapy, chemo-immunotherapy, or investigational agents < days from the date of randomisation or  half-lives of the agent, whichever is longer. Most recent non-cytotoxic targeted therapy < days from the date of randomisation.
Systemic cytotoxic therapy within  weeks of treatment
Prior cytotoxic or cyclosporin treatment for HLH.
Patients with prior cytotoxic chemotherapy are eligible to participate if they have been progression free for at least  months since the initiation of cytotoxic chemotherapy
Candidates for cytotoxic chemotherapy
A drug provided as maintenance therapy following cytotoxic chemotherapy will be considered to be part of that regimen.
Anyone with a second malignancy expected to require cytotoxic chemotherapy or immune modulating therapy within  months of enrollment
 weeks from prior cytotoxic therapy
Any prior cytotoxic chemotherapy except Temozolomide
Patients must have had prior cytotoxic therapy for their disease; patients with diffuse large B-cell lymphoma must have been treated with at least  prior cytotoxic therapies
Patients must have received at least  line of cytotoxic chemotherapy
Patients may have had up to two prior cytotoxic chemotherapy regimens for their disease (immunological or targeted therapy e.g. vaccine, IL-, B-RAF inhibitors, will not be considered prior cytotoxic chemotherapy). Patient should not have been treated with Docetaxel, Paclitaxel or other taxanes.
More than  prior cytotoxic chemotherapy regimen for advanced disease
Patient has had prior cytotoxic chemotherapy for the treatment of metastatic melanoma; however, patients who are randomized to the physicians choice arm and treated with cytotoxic chemotherapy as part of this study will be allowed to cross over to receive their assigned molecularly guided therapy should disease progression occur and they meet the specific eligibility requirements of the molecularly guided agent
Positive cytotoxic crossmatch
Anyone with a second malignancy expected to require cytotoxic chemotherapy or immune modulating therapy within  months of enrollment
Patient has received more than one line of cytotoxic chemotherapy
Subject must have had at least one prior cytotoxic chemotherapy regimen for unresectable or metastatic disease. Prior taxane therapy is allowed.
Concurrent anti-cancer cytotoxic chemotherapy
Use of cytotoxic chemotherapy within  days of registration
Prior cytotoxic chemotherapy or biologic therapy for CRPC
Prior treatment with more than one line of cytotoxic chemotherapy; prior treatment with one line of cytotoxic chemotherapy is permitted; prior treatment with targeted therapy (such as ipilimumab, anti-programmed cell death  [PD] and BRAF inhibitor) is permitted
At least  days from last cytotoxic chemotherapy
Scheduled to start a new chemotherapy regimen (any line, combination cytotoxic chemotherapy with targeted agents are allowed)
Treatment with cytotoxic chemotherapy within  weeks prior to registration
Patient has received an investigational agent or cytotoxic chemotherapy (excluding hydroxyurea) within  days of study entry
Received cytotoxic chemotherapy within  days (or  days for nitrosureas or mitomycin C) prior to the first scheduled dose of MEDI.
Cytotoxic chemotherapy within  weeks.
 days from administration of prior cytotoxic therapy with the following exceptions:
About to begin either oral or cytotoxic chemotherapy
Eligible patients must not be currently undergoing standard cytotoxic chemotherapy
Individuals who are actively undergoing standard cytotoxic chemotherapy
 month   years following completion of cytotoxic chemotherapy treatment for any cancer, and are experiencing neuropathy
Planned cytotoxic chemotherapy during the WBRT only; patients may have had prior chemotherapy
Treatment with cytotoxic chemotherapy within the preceding four weeks
Patients who have not had any cytotoxic chemotherapy within  days of beginning the study
Currently on or expected to start cytotoxic chemotherapy within  week of study enrollment
Participants who have received cytotoxic chemotherapy within  year prior to screening breast MRI
Other cytotoxic agents:  weeks
Subjects must have received cytotoxic chemotherapy within  months of consent date (measured from the start date of chemotherapy).
All previous cytotoxic chemotherapy, monoclonal antibody therapy, or immune therapy must be washed out  weeks before apheresis and must be completed at least  weeks prior to pre-infusion lymphodepletive chemotherapy.
Other cytotoxic agents:  weeks
Cytotoxic chemotherapy within  weeks prior to study enrollment
Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within defined values prior to start of study treatment
